| CAS ID: | 61477-96-1 |
| Molecular Formula: | C23H27N5O7S |
| Molecular Weight: | 517.6 g/mol |
| Monoisotopic Mass: | 517.1631 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | Isipen | PIPERACILLIN SODIUM | PIPRACIL | Piperacil | CL 227,193 | Pentacillin | PIPRIL | PIPERACILLIN | T-1220 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1 | See All |
| InChI Key: | IVBHGBMCVLDMKU-GXNBUGAJSA-N | |
| Smiles: | CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4ccccc4)C(=O)C1=O | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 17485505 | Target ID | |
| Uniprot ID | Name | ||
| Model | human | Fibrosis Disease | Cystic fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT01694069 | Disease | Cystic fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | September 26, 2012 | Last Verified | March 18, 2014 |
| Sponsor | West Virginia University | ||
Trial Record 2
| ClinicalTrial ID | NCT02840136 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Suspended |
| First Received | July 21, 2016 | Last Verified | June 13, 2018 |
| Sponsor | University Ghent | ||
Trial Record 3
| ClinicalTrial ID | NCT00153634 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | September 12, 2005 | Last Verified | March 13, 2008 |
| Sponsor | Seattle Children's Hospital | ||
Trial Record 4
| ClinicalTrial ID | NCT01983787 | Disease | Cystic fibrosis |
| Phase | Status | Completed | |
| First Received | November 14, 2013 | Last Verified | December 11, 2015 |
| Sponsor | University of Aarhus | ||